IDEAYA Biosciences, Inc.

IDYA

IDEAYA Biosciences, Inc.

IDYA

Insider Sentiment (TTM):

Last Purchase:2026-03-02Last Sale:2024-05-29Shares Purchased (TTM):50,000Shares Sold (TTM):0

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:92,883,238Shares Outstanding:88,699,754Institutional Ownership Pct.:104.72%

Earnings Market Reaction:

Filing Date:2026-08-04Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	273	158	113	299	115	130	84	400	183	108	157	152
Marketable Securities Current	556	514	527	488	555	563	592	520	519	590	368	317
Prepaid Expense And Other Assets Current	20	18	21	16	16	15	13	12	12	11	8	7
Receivables Net Current	-	-	-	-	-	-	0	0	0	0	0	7
Contract With Customer Asset Net Current	15	7	6	-	-	-	0	-	-	-	-	-
Assets Current	864	696	667	803	686	708	690	932	713	709	533	482
Restricted Cash Noncurrent	1	1	1	1	1	1	1	1	1	1	1	1
Marketable Securities Noncurrent	414	302	410	350	322	359	406	280	251	243	107	42
Property Plant And Equipment Net	8	9	8	8	9	9	9	8	7	7	6	6
Operating Lease Right Of Use Asset	22	23	23	24	24	24	19	18	1	2	2	1
Assets	1,310	1,030	1,109	1,185	1,041	1,101	1,124	1,240	974	962	649	533
Liabilities And Stockhold…
Other Assets Noncurrent	-	-	-	-	-	-	-	-	0	0	0	0
Liabilities Current
Accounts Payable Current	31	21	18	18	17	18	15	13	16	6	7	5
Accrued Liabilities Current	51	44	41	45	38	33	30	28	24	18	19	16
Contract With Customer Liability Current	-	-	-	0	-	-	-	-	-	-	-	1
Operating Lease Liability Current	1	0	0	0	0	0	0	0	1	1	2	2
Liabilities Current	83	65	59	65	55	51	46	41	41	25	27	25
Contract With Customer Liability Noncurrent	-	-	-	2	-	-	-	-	-	-	-	-
Operating Lease Liability Noncurrent	28	28	28	27	26	26	19	19	1	1	1	-
Liabilities	111	93	86	93	82	77	65	59	42	26	28	25
Stockholders Equity
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	2,148	1,773	1,757	1,743	1,731	1,718	1,681	1,669	1,374	1,324	969	823
Accumulated Other Comprehensive Income Loss Net Of…	-2	-0	2	2	2	2	1	4	-1	-1	1	-1
Retained Earnings Accumulated Deficit	-948	-835	-737	-653	-773	-695	-623	-493	-441	-388	-348	-314
Stockholders Equity	1,199	937	1,023	1,092	960	1,024	1,059	1,180	932	935	621	508
Liabilities And Stockholders Equity	1,310	1,030	1,109	1,185	1,041	1,101	1,124	1,240	974	962	649	533
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	300	300	300	300	300	300	300	300	300	300	300	300
Common Stock Shares Issued	96	88	88	88	88	88	87	86	76	75	65	59
Shares Outstanding	96	88	88	88	88	88	87	86	76	75	65	59

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	2.33%	27.57%	22.92%	-	-	-	-	-	-	-	-	-
2025	12.06%	20.39%	38.03%	1.78%	11.24%	20.98%	16.86%	15.49%	14.17%	7.57%	-0.85%	-7.93%
2024	-14.50%	-17.87%	-0.84%	9.72%	-14.44%	-18.61%	-8.80%	-16.13%	-21.27%	-9.10%	-18.05%	-14.77%
2023	-	-	-	16.75%	5.80%	0.27%	8.10%	21.60%	44.19%	0.66%	-4.64%	-6.45%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	10.45	10.74	11.34	12.44	12.39	13.92	14.97	22.93	17.50	28.42	19.65	19.37
Quick Ratio	10.21	10.45	10.97	12.20	12.10	13.62	14.68	22.63	17.22	28.00	19.38	19.10
Working Capital	781.35M	631.28M	607.91M	738.15M	630.26M	657.03M	643.64M	891.56M	672.44M	684.39M	505.53M	457.29M
Leverage & Debt
Debt to Equity	0.09	0.10	0.08	0.09	0.09	0.07	0.06	0.05	0.05	0.03	0.05	0.05
Debt Ratio	0.08	0.09	0.08	0.08	0.08	0.07	0.06	0.05	0.04	0.03	0.04	0.05
Efficiency & Turnover
Asset Turnover TTM	0.20	0.21	0.20	0.18	0.01	0.01	0.01	0.00	0.02	0.02	0.05	0.05
Days Sales Outstanding TTM	-	-	-	-	-	-	0.55	312.76	2.46	5.69	1.79	78.89
Receivables Turnover TTM	-	-	-	-	-	-	666.67	1.17	148.58	64.20	204.24	4.63
Per Share Metrics
Diluted EPS TTM	-1.90	-1.58	-1.28	-1.79	-3.75	-3.48	-3.36	-2.07	-1.97	-1.72	-1.96	-1.72
Free Cash Flow Per Share TTM	-1.08	-1.01	-0.85	-0.51	-2.68	-3.03	-3.08	-1.78	-1.72	-1.80	-2.04	-1.94
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-92.66%	-81.44%	-72.84%	-97.23%	-5,488.94%	-5,147.81%	-4,671.07%	-5,729.08%	-1,600.08%	-1,026.55%	-574.85%	-506.54%
Net Profit Margin TTM	-74.75%	-62.17%	-51.99%	-74.82%	-4,740.03%	-4,386.90%	-3,921.10%	-4,540.40%	-1,285.34%	-831.30%	-483.05%	-439.48%
Growth Metrics
Net Revenue Growth (1Y)	3,244.67%	3,118.14%	3,024.43%	5,376.27%	-41.48%	-54.85%	-70.07%	-83.30%	-73.51%	-67.32%	-54.08%	-52.91%
Net Income Growth (1Y)	-47.25%	-54.39%	-58.58%	-9.76%	115.82%	138.25%	142.98%	72.59%	107.33%	88.77%	92.59%	95.97%
EPS Growth (1Y)	-49.31%	-54.57%	-61.76%	-12.14%	90.18%	102.52%	71.12%	20.14%	49.59%	21.57%	38.76%	31.63%
Valuation Metrics
P/E TTM	-19.60	-21.10	-26.90	-14.99	-5.60	-4.71	-7.65	-15.33	-17.80	-25.57	-18.12	-15.68
P/B TTM	2.86	3.15	2.99	2.21	1.94	1.41	1.98	2.31	2.94	3.52	3.30	3.19
P/S TTM	14.65	13.12	13.99	11.21	265.67	206.75	299.88	696.01	228.85	212.56	87.52	68.93
Market Cap	3.43B	2.96B	3.06B	2.41B	1.86B	1.45B	2.10B	2.73B	2.74B	3.30B	2.05B	1.62B
Enterprise Value	3.16B	2.80B	2.95B	2.11B	1.74B	1.32B	2.01B	2.33B	2.55B	3.19B	1.89B	1.47B
Calculated Values
Free Cash Flow TTM	-99.61M	-89.27M	-74.80M	-45.06M	-236.92M	-267.98M	-251.44M	-153.27M	-134.36M	-134.85M	-117.59M	-116.38M
Net Debt	-272.59M	-158.80M	-113.84M	-299.73M	-115.45M	-130.80M	-85.18M	-401.19M	-183.96M	-109.10M	-157.78M	-152.57M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-03-02Purchase

Owner: Stein, Jeffrey

Title: -

Shares: 50,000

Price/Share: $32.96

Value: $1,648,000.00

Shares Owned: 54,281

Relationship: Director

Ownership: Direct

2024-05-29Sale

Owner: White, Michael Anthony

Title: Chief Scientific Officer

Shares: 28,500

Price/Share: $36.50

Value: $1,040,250.00

Shares Owned: -

Relationship: Officer

Ownership: Direct

2024-05-16Sale

Owner: Hata, Yujiro S

Title: President and CEO

Shares: 34,433

Price/Share: $42.05

Value: $1,447,907.65

Shares Owned: 677,887

Relationship: Director,Officer

Ownership: Direct

2024-02-09Sale

Owner: Ruiz, Briseno Andres

Title: See Remarks

Shares: 2,000

Price/Share: $46.02

Value: $92,040.00

Shares Owned: 24,531

Relationship: Officer

Ownership: Direct

2024-02-09Sale

Owner: Hata, Yujiro S

Title: President and CEO

Shares: 23,557

Price/Share: $45.54

Value: $1,072,785.78

Shares Owned: 677,887

Relationship: Director,Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-03-02	Stein, Jeffrey	Director	-	Direct	Purchase	50,000	32.96	$1,648,000.00	54,281	4
2024-05-29	White, Michael Anthony	Officer	Chief Scientific Officer	Direct	Sale	28,500	36.50	$1,040,250.00	0	4
2024-05-16	Hata, Yujiro S	Director,Officer	President and CEO	Direct	Sale	34,433	42.05	$1,447,907.65	677,887	4
2024-02-09	Ruiz, Briseno Andres	Officer	See Remarks	Direct	Sale	2,000	46.02	$92,040.00	24,531	4
2024-02-09	Hata, Yujiro S	Director,Officer	President and CEO	Direct	Sale	23,557	45.54	$1,072,785.78	677,887	4
2024-02-01	Hata, Yujiro S	Director,Officer	President and CEO	Direct	Sale	628	45.00	$28,260.00	677,887	4
2024-01-22	Ruiz, Briseno Andres	Officer	See Remarks	Direct	Sale	2,000	42.03	$84,060.00	26,531	4
2024-01-16	Hata, Yujiro S	Director,Officer	President and CEO	Direct	Sale	62,739	40.17	$2,520,225.63	677,887	4
2024-01-12	Ruiz, Briseno Andres	Officer	See Remarks	Direct	Sale	2,000	38.01	$76,020.00	28,531	4
2023-12-15	Throne, Jason	Officer	Chief Legal Officer	Direct	Sale	10,000	35.04	$350,400.00	0	4
2023-12-15	Hata, Yujiro S	Director,Officer	President and CEO	Direct	Sale	75,000	35.03	$2,627,250.00	677,887	4
2023-12-14	Ruiz, Briseno Andres	Officer	See Remarks	Direct	Sale	2,000	34.00	$68,000.00	30,531	4
2023-11-03	Throne, Jason	Officer	Chief Legal Officer	Direct	Sale	5,163	30.09	$155,354.67	0	4
2023-09-12	Throne, Jason	Officer	Chief Legal Officer	Direct	Sale	1,000	30.01	$30,010.00	0	4
2023-09-05	Throne, Jason	Officer	Chief Legal Officer	Direct	Sale	1,737	30.03	$52,162.11	0	4
2023-09-01	Ruiz, Briseno Andres	Officer	See Remarks	Direct	Sale	2,000	30.01	$60,020.00	32,531	4
2023-08-29	Stone, Paul A.	Officer	Chief Financial Officer	Direct	Sale	5,000	28.87	$144,350.00	9,303	4
2023-08-21	Stone, Paul A.	Officer	Chief Financial Officer	Direct	Sale	978	26.40	$25,819.20	14,303	4
2023-08-18	Stone, Paul A.	Officer	Chief Financial Officer	Direct	Sale	3,822	26.38	$100,824.36	15,281	4
2023-08-09	Stone, Paul A.	Officer	Chief Financial Officer	Direct	Sale	2,500	25.05	$62,625.00	19,303	4
2023-08-09	Throne, Jason	Officer	Chief Legal Officer	Direct	Sale	5,000	25.09	$125,450.00	0	4
2023-07-10	Throne, Jason	Officer	Chief Legal Officer	Direct	Sale	9,485	23.00	$218,155.00	0	4
2023-05-31	Throne, Jason	Officer	Chief Legal Officer	Direct	Sale	432	23.00	$9,936.00	0	4
2023-05-22	Throne, Jason	Officer	Chief Legal Officer	Direct	Sale	500	23.00	$11,500.00	0	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

104.72%

Inst. Shares: 92,883,238

Shares Outstanding: 88,699,754

2025-12-31

105.67%

Inst. Shares: 93,504,022

Shares Outstanding: 88,485,238

2025-09-30

104.23%

Inst. Shares: 92,268,789

Shares Outstanding: 88,526,781

2025-06-30

105.96%

Inst. Shares: 93,743,785

Shares Outstanding: 88,472,197

2025-03-31

101.09%

Inst. Shares: 89,321,314

Shares Outstanding: 88,356,335

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	92,883,238	88,699,754	104.72%
2025-12-31	93,504,022	88,485,238	105.67%
2025-09-30	92,268,789	88,526,781	104.23%
2025-06-30	93,743,785	88,472,197	105.96%
2025-03-31	89,321,314	88,356,335	101.09%
2024-12-31	87,192,664	81,678,069	106.75%
2024-09-30	86,714,012	86,188,510	100.61%
2024-06-30	77,828,800	77,962,730	99.83%
2024-03-31	74,405,214	75,108,484	99.06%
2023-12-31	62,231,780	57,519,929	108.19%
2023-09-30	56,370,506	59,999,449	93.95%
2023-06-30	51,583,287	56,251,130	91.70%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

IDEAYA Biosciences, Inc. (IDYA) — SEC Financial Statements & Analysis

IDEAYA Biosciences, Inc. (IDYA) is a pharmaceutical preparations company, incorporated in DE. IDEAYA Biosciences, Inc. trades on Nasdaq as: IDYA. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), IDEAYA Biosciences, Inc. reported a 3244.67% year-over-year revenue growth, a Debt-to-Equity ratio of 0.09x, a Price-to-Sales (P/S) ratio of 14.65x (TTM), a Price-to-Book (P/B) ratio of 2.86x (TTM), at a market cap of $3.43B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 3244.67%
Debt To Equity: 0.09x
P/S TTM: 14.65x
P/B TTM: 2.86x
Market Cap: $3.43B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is IDEAYA Biosciences, Inc. in?

IDEAYA Biosciences, Inc. (IDYA) operates in the Pharmaceutical Preparations industry.

What is IDYA's market cap?

IDEAYA Biosciences, Inc. (IDYA) has a market capitalization of $3.43B as of 2026-06-30.

What exchange does IDYA trade on?

IDEAYA Biosciences, Inc. (IDYA) trades on the Nasdaq.

Where is IDEAYA Biosciences, Inc. incorporated?

IDEAYA Biosciences, Inc. is incorporated in DE.